PharmaCyte Biotech, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended October 31, 2023; filed December 15, 2023. PharmaCyte is a pre-revenue biotechnology company developing Cell-in-a-Box cellular therapies, including CypCaps for locally advanced pancreatic cancer (LAPC), as well as programs for diabetes and malignant ascites.
Financial highlights
| Metric | Three months ended Oct. 31, 2023 | Six months ended Oct. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $1.410 million | $3.485 million | $2.319 million; $3.999 million |
| Net income (loss) | $2.790 million | $(0.393) million | $(1.881) million; $(3.426) million |
| Net loss attributable to common stockholders | $(2.258) million | $(9.033) million | $(1.881) million; $(3.426) million |
| Basic and diluted loss per share | $(0.26) | $(0.85) | $(0.09); $(0.17) |
- Cash and liquidity: Cash and cash equivalents were $73.425 million at October 31, 2023, versus $68.040 million at April 30, 2023. Current assets were $73.748 million and current liabilities $5.240 million; reported working capital was approximately $68 million. Total assets were $78.878 million.
- Cash flow: Six-month operating cash use was $1.641 million, with no investing cash flows. Financing provided $7.028 million, including net preferred-stock proceeds, offset in large part by $26.622 million of common-stock repurchases. Cash increased $5.385 million.
- Margins and debt: With no revenue, operating margins are not meaningful. No conventional borrowings are reported at period-end. Series B preferred stock is debt-like and redeemable; the balance sheet includes $4.095 million of accrued redemptions and dividends, plus $11.504 million of warrant liability and $4.069 million of derivative liability.
- Preferred-stock impact: Six-month common-stock loss includes $0.907 million of preferred dividends and $7.733 million of preferred-stock accretion. The quarterly net income was driven by noncash fair-value gains, not operating revenue: the six-month statement records a $2.623 million gain on warrant remeasurement, partly offset by a $1.299 million derivative remeasurement expense.
Changes versus the prior comparable periods
- Operating expenses fell 39% in the quarter and 13% for the six-month period year over year. Management attributed the decreases mainly to lower research and development, compensation, legal and professional, and consulting costs; spending on development programs was curtailed during the Board’s business review.
- Interest income rose to $0.894 million for the quarter and $1.770 million for six months, from $0.439 million and $0.579 million, respectively, reflecting higher interest rates.
- Common-stock repurchases were substantial: 8,163,988 shares for $26.622 million during the six months. The company also raised $35 million gross through its May 2023 Series B preferred and warrant private placement; net preferred-stock proceeds were $33.650 million.
- Shares outstanding were 8,699,992 at October 31, compared with 16,793,980 at April 30, while treasury shares rose to 12,972,086. The share count subsequently fell to 8,615,640 as of December 13, after further repurchases.
Outlook, commentary, and risks
- Management said existing cash should fund operating expenses for at least 12 months after issuance of the financial statements, but noted that future capital needs are uncertain and additional financing may not be available on acceptable terms.
- The FDA clinical hold on the LAPC IND, imposed in 2020, remains unresolved. The company reports completing product stability studies and several other requested studies; a two-pig pilot study is complete and preliminary data are under review. A planned 90-pig study has not commenced and may be delayed by supply and manufacturing issues, spending restraint, and the company’s review of its relationship with SG Austria.
- The Board has curtailed spending on development programs while reviewing strategy and the SG Austria relationship. The company says licensed patents have expired and relevant technology know-how resides with SG Austria; failure to establish an acceptable framework could lead it to reconsider LAPC, diabetes, and malignant-ascites programs. The cannabis program is not being funded.
- Series B terms include 4% annual dividends, monthly redemption installments, potential cash premiums, and a 15% dividend rate during specified triggering events. The first two installments were designated for cash redemption. Warrants and embedded preferred-stock derivatives are Level 3 fair-value liabilities, making reported earnings sensitive to valuation assumptions.
- After quarter-end, PharmaCyte agreed to invest $5 million in Femasys convertible notes and related warrants. It also approved executive and director cash compensation and option grants. These subsequent events may affect liquidity and dilution.
- Management concluded disclosure controls were not effective because of a material weakness: insufficient accounting personnel with appropriate GAAP and SEC-reporting expertise. The filing reports no material pending litigation.
Most important facts for investors to verify
- Progress and remaining requirements to lift the FDA clinical hold, including timing, results, and funding for the 90-pig study.
- Whether PharmaCyte can secure an acceptable relationship and reliable manufacturing arrangements with SG Austria, given its dependence on SG Austria’s know-how.
- Cash runway after preferred-stock redemption obligations, subsequent Femasys investment, and ongoing repurchases and compensation commitments.
- Series B redemption, dividend, premium, and triggering-event terms, and the potential common-share dilution from preferred conversions and 18.6 million outstanding warrants.
- Whether the company remediates the material weakness in internal controls and improves financial-reporting reliability.